Androgen deprivation therapy, in combination with novel anti-AR or taxanes, represents a fundamental strategy for the treatment of hormone-sensitive [2,3,4,5] and metastatic castration-resistant PC (mCRPC) [5,6,7]. Here, AR is linked to pachyonychia congenita.